Current and historical daily PE Ratio for JNJ (
Johnson & Johnson
) from 1990 to Apr 17 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Johnson & Johnson stock (JNJ) PE ratio as of Apr 17 2024 is 11.95.
More Details
Johnson & Johnson (JNJ) PE Ratio (TTM) Chart
Johnson & Johnson (JNJ) PE Ratio (TTM) Historical Data
View and export this data going back to 1990. Start your Free Trial
Total 1209
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Johnson & Johnson PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-04-18 | 11.9 | 2024-02-12 | 13.0 |
| 2024-04-16 | 11.9 | 2024-02-09 | 12.9 |
| 2024-04-15 | 12.2 | 2024-02-08 | 12.9 |
| 2024-04-12 | 12.2 | 2024-02-07 | 13.1 |
| 2024-04-11 | 12.3 | 2024-02-06 | 13.1 |
| 2024-04-10 | 12.4 | 2024-02-05 | 12.9 |
| 2024-04-09 | 12.6 | 2024-02-02 | 12.9 |
| 2024-04-08 | 12.5 | 2024-02-01 | 13.1 |
| 2024-04-05 | 12.6 | 2024-01-31 | 13.1 |
| 2024-04-04 | 12.6 | 2024-01-30 | 13.1 |
| 2024-04-03 | 12.7 | 2024-01-29 | 13.2 |
| 2024-04-02 | 13.0 | 2024-01-26 | 13.2 |
| 2024-04-01 | 13.0 | 2024-01-25 | 13.2 |
| 2024-03-28 | 13.1 | 2024-01-24 | 13.1 |
| 2024-03-27 | 13.0 | 2024-01-23 | 13.2 |
| 2024-03-26 | 12.9 | 2024-01-22 | 13.4 |
| 2024-03-25 | 12.8 | 2024-01-19 | 13.3 |
| 2024-03-22 | 12.8 | 2024-01-18 | 13.3 |
| 2024-03-21 | 12.9 | 2024-01-17 | 13.3 |
| 2024-03-20 | 12.9 | 2024-01-16 | 13.3 |
| 2024-03-19 | 12.9 | 2024-01-12 | 13.4 |
| 2024-03-18 | 12.9 | 2024-01-11 | 13.3 |
| 2024-03-15 | 13.1 | 2024-01-10 | 13.4 |
| 2024-03-14 | 13.2 | 2024-01-09 | 13.3 |
| 2024-03-13 | 13.3 | 2024-01-08 | 13.3 |
| 2024-03-12 | 13.4 | 2024-01-05 | 13.3 |
| 2024-03-11 | 13.3 | 2024-01-04 | 13.3 |
| 2024-03-08 | 13.2 | 2024-01-03 | 13.3 |
| 2024-03-07 | 13.1 | 2024-01-02 | 13.2 |
| 2024-03-06 | 13.2 | 2023-12-29 | 12.9 |
| 2024-03-05 | 13.2 | 2023-12-28 | 12.9 |
| 2024-03-04 | 13.2 | 2023-12-27 | 11.6 |
| 2024-03-01 | 13.4 | 2023-12-26 | 11.6 |
| 2024-02-29 | 13.3 | 2023-12-22 | 11.5 |
| 2024-02-28 | 13.3 | 2023-12-21 | 11.5 |
| 2024-02-27 | 13.3 | 2023-12-20 | 11.4 |
| 2024-02-26 | 13.3 | 2023-12-19 | 11.6 |
| 2024-02-23 | 13.4 | 2023-12-18 | 11.5 |
| 2024-02-22 | 13.3 | 2023-12-15 | 11.5 |
| 2024-02-21 | 13.1 | 2023-12-14 | 11.7 |
| 2024-02-20 | 13.0 | 2023-12-13 | 11.6 |
| 2024-02-16 | 12.9 | 2023-12-12 | 11.5 |
| 2024-02-15 | 13.0 | 2023-12-11 | 11.5 |
| 2024-02-14 | 12.9 | 2023-12-08 | 11.5 |
| 2024-02-13 | 12.9 | 2023-12-07 | 11.5 |
Johnson & Johnson (JNJ) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Johnson & Johnson
NAICS : 325412
SIC : 2834
ISIN : US4781601046
Share Class Description:
JNJ: Ordinary SharesCompare
Compare
Traded in other countries / regions
JNJ.USA0R34.UKJNJB34.BrazilJNJ.ArgentinaJNJ.CanadaJNJ.GermanyJNJ.Mexico1JNJ.ItalyJNJ.AustriaJNJ_KZ.KazakhstanJNJ.ChileJNJ.PeruJNJ.Ukraine IPO Date
1944-09-25Description
Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. The consumer group is being divested in 2023 under the new name Kenvue. Geographically, just over half of total revenue is generated in the United States.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers